BioSpace News Archive

scPharmaceuticals Inc. (Nasdaq: SCPH) today announced that scPharmaceuticals’ management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 9, 2022, to discuss third quarter financial results and provide a business update.

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the completion of enrollment in a Phase 1 healthy volunteer study to assess the safety, tolerability and pharmacokinetics (PK) of its orally administered, novel, broad-spectrum antiviral candidate CC-42344 for the treatment of pandemic and seasonal influenza A.

Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a clinical stage biopharmaceutical company developing viral immunotherapies, today announced a collaboration with the University of Pennsylvania (Penn) to study the impact of novel viral immunotherapies based on Candel’s proprietary enLIGHTEN™ Discovery Platform to strengthen the effects of Penn’s CAR-T cell therapies in solid tumor models.

QSAM Biosciences, Inc. (OTCQB: QSAM) today announces the addition of Rutgers Cancer Institute of New Jersey (RCINJ) as a clinical trial site approved to begin enrolling patients into the Phase 1 study evaluating CycloSam® in treating patients with bone cancer that either originated in or has metastasized to the bone.

Soon after the onset of the COVID-19 pandemic, it became increasingly evident that necessary infection control measures also had unintended consequences for Canadians living with diabetes.

Codagenix Inc., a clinical-stage synthetic biology company with a rational virus design platform for viral vaccines and immuno-oncology therapeutics, in collaboration with the Serum Institute of India Pvt. Ltd., today announced dosing has been initiated in an international, multi-center, randomized placebo-controlled Phase 3 clinical trial of CoviLiv.

Johnson & Johnson Vision Care, Inc.,‡ a global leader in eye health and part of Johnson & Johnson MedTech,§ will present new data on the positive effects of wearing blue-violet light filtering contact lenses* at the 2022 American Academy of Optometry annual meeting in San Diego, October 26 – 29.

Orionis Biosciences today will present preclinical data supporting its Allo-GlueTM protein degradation platform for discovery and rational design of small molecule molecular glues at the 5th Annual Targeted Protein Degradation Summit, taking place October 25 – 28 in Boston.

Complete Genomics, part of MGI, celebrates the US commercial launch of their DNBSEQTM sequencing product line at the American Society of Human Genetics Annual Meeting, from October 25-29, in Los Angeles.

Verona Pharma plc announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.